Jason Aaron Salganick, MD

Ironwood Cancer and Research Centers

Division of Oncology and Hematology

Myeloma & Lymphoma Sub Division

Education:

7/2000-6/2004	Fellowship- Med/Peds at M.D. Anderson Cancer Center
7/1996-6/2000	Tulane University Medical Center Internship & Residency: MED/PEDS
7/1992-6/1996	University of Chicago, Pritzker School of Medicine- MD, 1996
9/1987-6/1992	Princeton University, Major: Medieval History- BA, 1992
9/1990-6/1991	Oxford University, Visiting Scholar- Medieval & New World History

Professional Experience:

5/2013 – Present Physician, Division Director of Myeloma & Lymphoma Sub Division

Ironwood Cancer & Research Centers, Phoenix, AZ

3/2008-4/30/2013 Physician, Arizona Oncology, Phoenix, AZ

8/2004-10/2007 Physician, Mt. Diablo Regional Cancer Center, Concord, CA

2004-Present Member, Investigational Review Board, John Muir Medical Center,

Concord Campus

Activities and Honors:

Certifications:

American Board of Internal Medicine- Hematology

American Board of Internal Medicine- Oncology

American Board of Internal Medicine

Awards, Honors and Committees:

PHOENIX Magazine Top Doctor Award

Clinical Assistant Professor, Creighton University

2010, Chairman, John C. Lincoln North Mountain Tumor Board, Monthly C.M.E. Event

2006, Case Presentation, 6th Annual U.C.S.F. Clinical Cancer Update, Squaw Valley, CA

2005, Oral Presentation, 5th Annual U.C.S.F. Clinical Cancer Update, Squaw Valley, CA

1996-1998, Chairman, Resident Physician's Section, Louisiana State Medical Society (two terms) representing 1500 Physicians in Training in Louisiana

Professional Memberships:

American Society of Clinical Oncology

American College of Physicians

Maricopa County Medical Society

American Medical Association

Publications:

Komenaka IK, Hibbard ML, Hsu CH, Low BG, **Salganick JA**, Bouton ME, Jha C. <u>Preoperative chemotherapy for operable breast cancer improves surgical outcomes in the community hospital setting</u>. Oncologist. 2011;16(6):752-9. Epub 2011 May 9.

Komenaka IK, Hsu CH, Martinez ME, Bouton ME, Low BG, **Salganick JA**, Nodora J, Hibbard ML, Jha C.

<u>Preoperative chemotherapy for operable breast cancer is associated with better compliance with adjuvant therapy in matched stage II and IIIA patients</u>. Oncologist. 2011;16(6):742-51. Epub 2011, May 9.

J. A. Salganick, C. O. Oyedeji, S. Patel, M. A. Burgess, L. L. Chen, R. S. Benjamin, J. C. Trent; M. D. Anderson Cancer Center, Houston, TX. <u>Differential sensitivity of rhabomyosarcoma cell line clones to EGF receptor inhibition with gefitinib</u>. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 9003, Abstract No: 9003.

Dejka M. Steinert, MD, L. Johnetta Blakely, MD, **Jason Salganick, MD**, Jonathan C. Trent, MD, PhD. Molecular Targets in Therapy for Human Soft-tissue and Bone Sarcomas. Current Oncology Reports 2003, 5:295-303.

Research Trials:

Sub investigator in Ironwood Cancer and Research Centers trials, please refer to website for details.

Other Activities:

He enjoys salsa dancing, scuba diving, mountain biking and strategic board games.